3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata
In a recent slideshow on one-drug wonders, Fool Brian Orelli pointed to three companies that have been very successful after launching their first major drug.
In the video below, he talks with Max Macaluso, the Fool's health care bureau chief, about three companies: Chelsea Therapeutics , MannKind , and Durata Therapeutics , which are looking to launch their first drug if the FDA agrees.
Chelsea Therapeutics is on its second attempt to have its low blood pressure medication Northera approved. MannKind is on its third attempt for its inhaled insulin Afrezza. And Durata Therapeutics is up for an FDA approval for its antibiotic Dalvance.
Another company looking for a big 2014
The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article 3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata originally appeared on Fool.com.
Brian Orelli, Max Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.